|
|
Blood, 15 September 2004, Vol. 104, No. 6, pp. 1624-1630.
Prepublished online as a Blood First Edition Paper on June 3, 2004; DOI 10.1182/blood-2003-12-4428.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
Deborah A. Thomas,
Susan O'Brien,
Jorge Cortes,
Francis J. Giles,
Stefan Faderl,
Srdan Verstovsek,
Alessandra Ferrajoli,
Charles Koller,
Miloslav Beran,
Sherry Pierce,
Chul S. Ha,
Fernando Cabanillas,
Michael J. Keating, and
Hagop Kantarjian
From the Departments of Leukemia, Lymphoma, and Radiation Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX.
Therapy of lymphoblastic lymphoma (LL) has evolved with use of chemotherapy regimens modeled after those for acute lymphocytic leukemia (ALL). We treated 33 patients with LL with the intensive chemotherapy regimens hyper-CVAD (fractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone) or modified hyper-CVAD used for ALL at our institution. Induction consolidation was administered with 8 or 9 alternating cycles of chemotherapy over 5 to 6 months with intrathecal chemotherapy prophylaxis, followed by maintenance therapy. Consolidative radiation therapy was given to patients with mediastinal disease at presentation. No consolidation with autologous or allogeneic stem cell transplantation was performed. At diagnosis, 80% were T-cell immunophenotype, 70% were stages III to IV, 70% had mediastinal involvement, and 9% had central nervous system (CNS) disease. Of the patients, 30 (91%) achieved complete remission, and 3 (9%) achieved partial response. Within a median of 13 months, 10 patients (30%) relapsed or progressed. Estimates for 3-year progression-free and overall survival for the 33 patients were 66% and 70%, respectively. Estimates for the patients with known T-cell immunophenotype were 62% and 67%, respectively. No parameters (eg, age, stage, serum lactate dehydrogenase [LDH],  2 microglobulin) appeared to influence outcome except for CNS disease at presentation. Modification of the hyper-CVAD regimen with anthracycline intensification did not improve outcome. Other modifications of the program could include incorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or those with residual mediastinal disease. (Blood. 2004;104:1624-1630)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Hunault, M. Truchan-Graczyk, D. Caillot, J.-L. Harousseau, S. Bologna, C. Himberlin, D. Guyotat, C. Berthou, P. Casassus, L. Baranger, et al.
Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial
Haematologica,
December 1, 2007;
92(12):
1623 - 1630.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jabbour, S. O'Brien, H. Kantarjian, G. Garcia-Manero, A. Ferrajoli, F. Ravandi, M. Cabanillas, and D. A. Thomas
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia
Blood,
April 15, 2007;
109(8):
3214 - 3218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Song, M. Barnett, R. Gascoyne, M Chhanabhai, D. Forrest, D. Hogge, J. Lavoie, S. Nantel, T. Nevill, J. Shepherd, et al.
Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes
Ann. Onc.,
March 1, 2007;
18(3):
535 - 540.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. B. Greenberg, P. A. Boria, A. Borgatti-Jeffreys, R. E. Raskin, and M. D. Lucroy
Phase II Clinical Trial of Combination Chemotherapy With Dexamethasone for Lymphoma in Dogs
J. Am. Anim. Hosp. Assoc.,
January 1, 2007;
43(1):
27 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Sandlund
Should Adolescents with NHL Be Treated as Old Children or Young Adults?
Hematology,
January 1, 2007;
2007(1):
297 - 303.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Thomas, H. M. Kantarjian, J. L. Jorgensen, S. Faderl, J. Cortes, F. Giles, G. Garcia-Manero, W. Wierda, A. Ferrajoli, F. Ravandi-Kashani, et al.
Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
1861 - 1861.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. J. DeAngelo
The Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia
Hematology,
January 1, 2005;
2005(1):
123 - 130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
